A revolutionary technique that promises to restore the sight of millions has been carried out for the first time worldwide in a British hospital.
Taking as little as 45 minutes, the procedure offers hope to those with age-related macular degeneration, the leading cause of blindness in adults globally.
It affects more than 600,000 adults in the UK, blighting the lives of a quarter of the over-60s.
In the breakthrough developed at University College London, doctors inserted a patch of stem cells into the retina of a woman who has lost her central vision.
They hope the procedure, carried out at Moorfields Eye Hospital in the capital, will restore the 60-year-old’s sight but will not know the outcome until December.
However, doctors said she suffered no complications and her eye is recovering well from the procedure.
This first operation has begun a clinical trial involving ten patients. If successful, the technique could be available on the NHS within two-and-a-half years.
The procedure, which has attracted the support of medical giant Pfizer, is carried out under local anaesthetic. It involves taking a single embryonic stem cell and growing it into a 6mm patch of 100,000 retinal pigment cells.
That patch is then rolled into a thin tube, which is injected through a tiny slit in the eye.
Once unfurled, it is placed behind the retina where scientists hope it will replace the faulty cells.
The operation is a milestone in the London Project to Cure Blindness established ten years ago with the aim of curing vision loss in patients with age-related macular degeneration.
The first step has been carried out on the wet form of the condition when a patient bleeds at the back of the eye. But scientists are confident it could also be used for the more common dry AMD, which affects 85 per cent of British sufferers.
The Latest on: Age-related macular degeneration
via Google News
The Latest on: Age-related macular degeneration
- Macular Degeneration Treatment Market is Worth US$11.4 Bn By 2026on September 6, 2019 at 4:14 am
The market is growing at striking CAGR around 6.6 % over the forecast time frame 2018 - 2026. Increase in age-related macular degeneration treatment (AMD) is expected to drive the growth of the global ...
- OpRegen appears well tolerated in dry AMDon September 5, 2019 at 11:08 am
COEUR D’ALENE, Idaho — In patients with dry age-related macular degeneration, the implantation of human embryonic stem cell-derived retinal pigment epithelial cells was mostly well tolerated, ...
- Age-related vision problems are commonon September 5, 2019 at 8:10 am
With aging adults, especially those with a family history of vision issues, age-related or not, as well as macular degeneration, regular visits to the eye doctor are recommended. “Eye issues can ...
- Clearside Biomedical Shares Rebound On Microinjector Licensing Deal With Regenxbioon September 4, 2019 at 7:20 am
RGNX), granting the latter worldwide rights to its proprietary in-office SCS Microinjector for the delivery of RGX-314 to the suprachoroidal space to treat wet age-related macular degeneration, or AMD ...
- Opthea’s Phase 2b Study of OPT-302 in Wet AMD to be Presented in Late-Breaking Session of EURETINAon September 4, 2019 at 2:30 am
Wet (neovascular) age-related macular degeneration, or wet AMD, is a disease characterized by the loss of vision of the middle of the visual field caused by degeneration of the central portion of ...
- Gyroscope Targets Age-Related Blindness with €55M Series Bon September 3, 2019 at 9:57 am
UK gene therapy biotech Gyroscope Therapeutics has secured €55.4M in Series B funding to target age-related macular degeneration. Life sciences investor Syncona, which is backed by the UK’s Wellcome ...
- Allegro Ophthalmics to Present the Results of Its Phase 2 Risuteganib Intermediate Dry Age-Related Macular Degeneration Study at the 19th EURETINA Conon September 3, 2019 at 5:00 am
Results of Allegro’s Ex-U.S. Proof-of-Concept Trial with Integrin Regulator ALG-1007 for Dry Eye Disease Will Be Presented at the 37 th Congress of the ESCRS In June, Allegro announced topline results ...
- Wet Age-Related Macular Degeneration Market Forecast 2019-2024 - Positive Clinical Trial Results and Increasing Approvals for Pipeline Drugson August 27, 2019 at 9:09 am
The global wet age-related macular degeneration (AMD) market attained a size of $6.9 billion in 2018, and it is expected to reach $10.4 billion by 2024, advancing at a CAGR of 7.1% during the forecast ...
- Dry Age-Related Macular Degeneration Market Insights, Epidemiology and Market Forecast-2028on August 26, 2019 at 6:54 am
1. Age-related Macular Degeneration affects approximately 1.8 million Americans aged 40 years and older. 2. Approximately 85–90% of the cases of macular degeneration are the "dry" type. 3. Age-Related ...
- Global Age-Related Macular Degeneration (AMD) Therapeutics Market 2019 - 2023: Analysis and Market Professional Research Report.on August 21, 2019 at 3:29 am
Aug 21, 2019 (The Expresswire) -- Age-Related Macular Degeneration (AMD) Therapeutics Industry 2019 Key trends, market drivers, challenges, standardization, deployment models, opportunities, future ...
via Bing News